Vertex Pharmaceuticals lifts forecast as non-CF portfolio heads into 53% second-half hurdle
Vertex Pharmaceuticals Incorporated lifted its yearly sales forecast as cystic-fibrosis treatments fueled a 12% rise in quarterly revenue. Shares traded almost flat around $470 following hours, after a 1.3% drop to $470.72 at the close.
